0000950170-23-029861.txt : 20230626
0000950170-23-029861.hdr.sgml : 20230626
20230626160751
ACCESSION NUMBER: 0000950170-23-029861
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230623
FILED AS OF DATE: 20230626
DATE AS OF CHANGE: 20230626
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Reinhart Harald
CENTRAL INDEX KEY: 0001835824
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38205
FILM NUMBER: 231042425
MAIL ADDRESS:
STREET 1: 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR
STREET 2: PUDONG
CITY: SHANGHAI
STATE: F4
ZIP: 201210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zai Lab Ltd
CENTRAL INDEX KEY: 0001704292
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4560 JINKE ROAD
STREET 2: BLDG. 1, 4F, PUDONG
CITY: SHANGHAI
STATE: F4
ZIP: 201210
BUSINESS PHONE: 862161632588
MAIL ADDRESS:
STREET 1: 4560 JINKE ROAD
STREET 2: BLDG. 1, 4F, PUDONG
CITY: SHANGHAI
STATE: F4
ZIP: 201210
4
1
ownership.xml
4
X0407
4
2023-06-23
0001704292
Zai Lab Ltd
ZLAB
0001835824
Reinhart Harald
C/O ZAI LAB LIMITED
314 MAIN STREET, 4TH FLOOR, SUITE 100
CAMBRIDGE
MA
02142
false
true
false
false
See Remarks
false
American Depositary Shares
2023-06-23
4
M
false
18250
25.30
A
40497
D
American Depositary Shares
2023-06-23
4
F
false
7182
25.30
D
33315
D
Restricted Share Units
0.00
2023-06-23
4
M
false
18250
0.00
D
American Depositary Shares
18250
54750
D
Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
ADSs acquired on vesting of Restricted Share Units. Each ADS represents ten Ordinary Shares of the issuer.
This transaction represents the disposition of shares to cover taxes.
Each Restricted Share Unit represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer.
The Restricted Share Units vest in equal annual installments over four years beginning on 06/25/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.
President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
/s/ Bruce Blefeld, Attorney-in-Fact
2023-06-26